Success with saxagliptin plus dapagliflozin

Adding a combination of DPP-4 and SGLT2 inhibitors to background metformin in poorly controlled type 2 diabetes patients achieves better results than adding either component alone, according to the results of a clinical trial.

More than 40% of poorly controlled patients receiving saxagliptin (SAXA) plus dapagliflozin (DAPA) achieved an A1C goal of <7%, with weight loss similar to DAPA alone and with very low hypoglycaemia risk, according to the results presented at  the conference of the European Association for the Study of